BioIVT, a Westbury, NC-based provider of biospecimens, research models and services for drug and diagnostic development, acquired XenoTech, a Kansas City, KS-based provider of products for ADME-Tox in vitro models and contract research services, from Sekisui Chemical, based in Japan.
The amount of the deal was not disclosed.
With the acquisition, BioIIVT will continue its commitment to provide its biopharmaceutical customers with a comprehensive portfolio of research models and services to help them reach their R&D goals faster. XenoTech’s product lines, which include microsomes, complement BioIVT’s portfolio of hepatocytes and other hepatic products. XenoTech’s expertise also combines with BioIVT’s strengths in drug transporter research, B-CLEAR® disposition studies, long-term HEPATOPAC® models, and other proprietary methodologies and will increase BioIVT’s capabilities to support and accelerate customer research.
Led by CEO Dr. Darren Warren, XenoTech provides tools and resources to advance the development of effective, safe drugs, specializing in ADME, DMPK and DDI testing of potential drug candidates
Led by CEO Dr. Richard Haigh, BioIVT is a provider of research models and value-added research services for drug discovery and development. The solutions enable scientists to understand the pharmacokinetics and drug metabolism of newly discovered compounds and their effects on disease processes.
FinSMEs
13/09/2022